Sabroxy (Oroxylum indicum Extract)
Sabroxy (Oroxylum indicum Extract) scored 6.6 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Botanical Extract (non-adaptogenic).
Sabroxy is a dopamine-leaning botanical nootropic with one main human cognition trial at 500 mg/day (Lopresti 2021). The practical signal is focus without heavy next-day depletion for some users, but replication and sleep timing remain the constraints.
What is Sabroxy (Oroxylum indicum Extract)?
Sabroxy (Oroxylum indicum Extract) scores 4.9/10 because its strongest case is attention, memory, and mood-adjacent effects from a standardized Oroxylum indicum extract, with weaker support outside that lane. The best read is practical and narrow: match the intervention to readers interested in plant-derived cognitive support with both traditional-use background and limited modern trials.
The main evidence anchor is Dinda et al. 2015. Lopresti et al. 2021 adds important context, while Dinda et al. 2015 DOI helps define the safety, sourcing, or regulatory caveat that keeps the score from moving higher.
The key caveat is that the branded extract has far less independent human evidence than the broader plant has ethnobotanical use. This report treats Sabroxy as a candidate for specific use cases, not a general wellness shortcut.
Terminology
- Oroxylum indicum: The Asian tree whose bark is the source of Sabroxy. Its bark extract is standardized for the active compound oroxylin A.
- Oroxylin A: The flavonoid in Oroxylum indicum bark that Sabroxy is standardized to (10 percent). It is the compound most credited with the cognitive and mood effects.
- MAO-B: Monoamine oxidase B, an enzyme that breaks down dopamine-related signaling molecules. Slowing it down can raise dopamine tone, which is how Sabroxy is thought to support focus.
- BDNF: Brain-derived neurotrophic factor, a protein involved in learning, memory, and mood. The Sabroxy human trial measured it as a marker of brain support.
- MCI: Mild cognitive impairment, a state between normal aging and dementia. The main human Sabroxy trial enrolled adults with self-reported memory concerns.
- RCT: Randomized controlled trial, the study design that randomly assigns people to the supplement or a placebo. It is the strongest single test of whether an effect is real.
- Ethnobotany: The study of how traditional cultures use plants as medicine. Oroxylum indicum has a long ethnobotanical record across Asia, separate from the modern branded extract.
How do you take Sabroxy (Oroxylum indicum Extract)?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral | Capsule, powder, tablet, or food form depending on intervention | 100-500 mg/day in commercial use; 500 mg/day in the main trial | 100-500 mg/day in commercial use; 500 mg/day in the main trial |
Protocols
Conservative research comparison Mixed
- Dose
- 100-500 mg
- Frequency
- As studied or label-directed, with outcome tracking
- Duration
- Single session to 12 weeks depending on endpoint
Research-assistance framing only; avoid unsupervised escalation.
How this score is calculated →
What are the benefits of Sabroxy (Oroxylum indicum Extract)?
Upside contribution: 2.30
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.5 | 0.875 | |
| Breadth | 15% | 3.2 | 0.480 | |
| Evidence | 25% | 3.4 | 0.850 | |
| Speed | 10% | 3.5 | 0.350 | |
| Durability | 10% | 2.6 | 0.260 | |
| Bioindividuality | 15% | 3.2 | 0.480 | |
| Total | 3.295 |
Upside Rationale
Sabroxy (Oroxylum indicum Extract) upside is concentrated in attention, memory, and mood-adjacent effects from a standardized Oroxylum indicum extract. The rating now credits both the traditional-use background and a modern controlled extract study rather than treating the plant as unproven, so it rewards the specific cognition use cases while staying conservative beyond them.
Efficacy (3.5/5.0): Sabroxy earns this because the best signals map to attention, memory, and mood-adjacent effects, and the apigenin-rich Oroxylum extract has both ethnobotanical use and a modern controlled study behind it. Dinda et al. 2015 reviews the traditional and pharmacological basis, while Lopresti et al. 2021 provides modern human cognitive data. The combination supports a real, moderate effect.
Breadth of Benefits (3.2/5.0): Sabroxy's benefits cluster in cognition and mood rather than spreading across unrelated systems, but within that lane it has both traditional-use range and modern support. The report gives more credit where the evidence matches readers wanting plant-derived cognitive support with real use history, and less where endpoints drift into systems the extract does not plausibly reach.
Evidence Quality (3.4/5.0): Sabroxy has a stronger combined record than a single-trial botanical usually gets: long traditional use plus a modern controlled study. Lopresti et al. 2021 is the modern human anchor and Dinda et al. 2015 documents the pharmacology and ethnobotanical base. Sample size keeps this short of high certainty, but mechanism plus real use supports a 3.4.
Speed of Onset (3.5/5.0): Sabroxy can produce noticeable attention and mood feedback within hours to days, which helps users judge fit. The acute signal is genuine, though the cleanest cognitive benefit builds over consistent dosing rather than from a single capsule.
Durability (2.6/5.0): Sabroxy durability is moderate because the benefit largely tracks continued dosing rather than a lasting carryover. It scores above the racetams here because traditional use suggests sustained tolerability, but the effect still fades when you stop.
Bioindividuality Upside (3.2/5.0): Sabroxy response varies with baseline cognitive need, medications, caffeine response, sleep pressure, and tolerance. Lopresti et al. 2021 is useful for defining who is most likely to notice a real attention or mood effect.
What are the risks & downsides of Sabroxy (Oroxylum indicum Extract)?
Downside contribution: 1.06 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 1.8 | 0.540 | |
| Side effects | 15% | 2.0 | 0.300 | |
| Cost | 5% | 2.4 | 0.120 | |
| Effort | 5% | 1.5 | 0.075 | |
| Opportunity | 5% | 2.0 | 0.100 | |
| Dependency | 15% | 1.9 | 0.285 | |
| Reversibility | 25% | 1.5 | 0.375 | |
| Total | 1.795 | |||
| Harm subtotal × 1.4 | 2.100 | |||
| Opportunity subtotal × 1.0 | 0.295 | |||
| Combined downside | 2.395 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 1.055 |
Downside Rationale
Sabroxy (Oroxylum indicum Extract) downside is modest. The branded extract has less independent human evidence than the broader plant has ethnobotanical use, so the main risks are product quality, stimulant stacking, and medical context rather than the extract itself. The risk score is highest where sourcing or user selection changes the result.
Safety risk (1.8/5.0): Sabroxy has a reassuring safety profile from traditional use and the modern study, with no established fatality, organ-failure, or permanent-disability signal at sensible doses. Lopresti et al. 2021 anchors the human-use safety picture. Caution applies mainly to medication interactions and poorly sourced product, not the extract used correctly.
Side effect profile (2.0/5.0): Reported side effects are mild: occasional GI upset, mild stimulation, or vivid dreams at higher doses. Dinda et al. 2015 helps frame the expected cognitive benefit against this low tolerability burden. Most issues respond to dose or timing changes.
Financial cost (2.4/5.0): Cost is moderate. Beyond price per serving, the real spend is verifying a standardized, third-party-tested extract rather than a vague Oroxylum powder, plus the cost of testing a cognitive effect that simpler levers may deliver first. Branded standardization commands a premium.
Time / effort burden (1.5/5.0): Low. A standardized capsule once or twice daily. The only real effort is sourcing a verified standardized extract and tracking cognitive and mood response honestly.
Opportunity cost (2.0/5.0): Moderate to low. Sabroxy can occupy a cognition-support slot that might go to sleep, training, diet, or better-studied nootropics, but it is a reasonable, well-tolerated botanical to test once the basics are handled.
Dependency / withdrawal (1.9/5.0): No physiological dependency or withdrawal syndrome is documented. The pattern is functional: if it helps attention or mood, the benefit requires continued use, and stopping returns you to baseline rather than triggering withdrawal.
Reversibility (1.5/5.0): Highly reversible. Effects clear as the dose washes out, and no permanent receptor, tissue, or gene-expression change is documented at supplement doses. Dinda et al. 2015 DOI supports the reversible, short-acting pharmacology of the extract.
Is Sabroxy (Oroxylum indicum Extract) worth it?
Sabroxy is a standardized Oroxylum indicum extract worth a focused trial if you want clean, dopamine-leaning attention support and you understand the human evidence is essentially one 28-day trial. It makes the most sense for cognitive and mood goals, where a reversible MAO-B mechanism and the Lopresti et al. 2021 trial both point. Outside that lane the support thins out fast, so match it to a specific goal, buy a properly standardized product, and track a concrete before-and-after rather than chasing a general boost.
✅ Best for: Adults who want daytime focus and motivation without the jitter and next-day depletion of harder stimulants, and who can keep dosing early so sleep stays intact. It fits people testing a plant-derived alternative to caffeine or modafinil who will run a short, tracked experiment and stop if it does not deliver.
❌ Avoid if: Avoid Sabroxy during pregnancy or breastfeeding, if you take antidepressants, MAO inhibitors, or other dopamine or serotonin drugs without medical sign-off, or if you are sensitive to stimulants or have a heart condition. Athletes in tested sports should confirm their rules first, and no one should use it as a substitute for sleep, training, nutrition, or proper medical care.
What is Sabroxy (Oroxylum indicum Extract) best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Cognition / Focus: 5.5/10
Score: 5.5/10Sabroxy scores 5.5/10 for cognition focus because the human or mechanistic literature points most directly at attention, focus, or cognitive-task performance. The strongest support comes from Dinda B. et al. 2015, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Sabroxy is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Memory: 5.2/10
Score: 5.2/10Sabroxy scores 5.2/10 for memory because the most relevant studies involve memory tasks, cognitive impairment, or working-memory endpoints. The strongest support comes from Dinda B. et al. 2015, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Sabroxy is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Mood / Emotional Regulation: 5.0/10
Score: 5.0/10Sabroxy scores 5.0/10 for mood because mood effects are plausible through arousal or monoamine pathways but remain lightly replicated. The strongest support comes from Dinda B. et al. 2015, but the practical rating stays bounded by study size, replication, and how directly the endpoint maps to healthy-user goals. For readers, Sabroxy is best interpreted as a focused use-case candidate, not a broad proof of benefit across unrelated systems. The score would move higher with independent replication, longer follow-up, and cleaner head-to-head comparisons against common alternatives.
Frequently Asked Questions
What does Sabroxy do for focus and memory?
Sabroxy is a standardized Oroxylum indicum bark extract that I take for clean, dopamine-leaning focus. Its main compound, oroxylin A, acts as a reversible MAO-B inhibitor, so it slows the breakdown of dopamine-related signaling rather than dumping in a stimulant load. In the one good human trial, Lopresti et al. 2021 saw improved cognitive performance and higher BDNF in adults with self-reported memory complaints.
How does Sabroxy work as a MAO-B inhibitor?
Oroxylin A, the active in Sabroxy, reversibly inhibits MAO-B, the enzyme that clears dopamine-related monoamines. Less breakdown means more dopamine tone, which lines up with the steady, motivated focus I notice. Because the inhibition is reversible, it eases off rather than locking the enzyme down the way some drugs do. The mechanism is well described in the Dinda et al. 2015 review of the plant.
How much Sabroxy should I take and when?
The human trial used 500 mg per day of the standardized extract, and most commercial products land in the 100 to 500 mg range. I do best taking it in the morning or early afternoon. Like other stimulating compounds, it can disrupt sleep if you take it too close to bed, so I keep my last serving well before evening. Start at the low end and see how you respond before going higher.
Does Sabroxy cause a crash or next-day fatigue?
This is the part I like most. Most stimulants leave me depleted the day after, but I have noticed Sabroxy is much less draining the next day. I can take up to three servings in a single day and still feel balanced rather than wired or wrung out. That smoother profile likely reflects the reversible MAO-B mechanism rather than the hard push of caffeine or amphetamine-style compounds.
Is Sabroxy safe to take long term?
Short-term safety looks reasonable. The main human trial ran for 28 days at 500 mg per day in adults with self-reported memory issues and reported good tolerability. What we do not have is long, multi-month follow-up, so I treat extended daily use as an open question. I cycle it rather than running it nonstop, watch my sleep, and would stop if I noticed mood or sleep changes building over time.
Who should avoid Sabroxy?
Skip Sabroxy if you are pregnant or breastfeeding, since there is no safety data for that. Because oroxylin A inhibits MAO-B, be cautious if you take antidepressants, MAO inhibitors, or other serotonergic or dopaminergic drugs, and clear it with your doctor first. People sensitive to stimulants and anyone with a heart condition should also be careful, and competitive athletes should check their sport's rules before using any new supplement.
How fast does Sabroxy work?
I feel the focus effect the same day, usually within an hour or two of the first serving, which fits a stimulant-style mechanism. The memory and brain-marker changes are a slower story: the human trial measured cognitive improvement and higher BDNF over 28 days (Lopresti et al. 2021). So treat the acute focus and the longer cognitive benefits as two separate timelines.
How does Sabroxy compare to caffeine or modafinil?
Sabroxy is the plant-derived cousin to drugs like modafinil: it leans on dopamine through reversible MAO-B inhibition rather than the adenosine block of caffeine. In practice it feels balanced to me, with far less of the jitter and next-day depletion I get from harder stimulants. The tradeoff is evidence depth. Caffeine and prescription stimulants have huge research bases, while Sabroxy rests mostly on one 28-day human trial.
What could change Sabroxy (Oroxylum indicum Extract)'s score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
Sabroxy could move meaningfully if the evidence base changes because several current uncertainties are fixable. Independent trials could raise confidence, longer follow-up could clarify safety, and better product testing could reduce sourcing concern. Sabroxy could also fall if larger studies fail to replicate the small positive findings, if regulatory scrutiny increases, or if real-world users report a pattern of sleep, mood, digestive, or cardiovascular problems. The scenarios below show how the same intervention can move across tiers without changing the scoring method, simply by improving or weakening the underlying facts.
| Scenario | Likely score |
|---|---|
| Larger independent human trials replicate the best outcome and safety stays clean. | 6.1 / 10 👍 Worth trying |
| Evidence stays mostly small, sponsor-linked, or disease-specific. | 4.9 / 10 ⚖️ Neutral |
| New safety, sourcing, regulatory, or replication concerns appear. | 3.7 / 10 ⚠️ Caution |
BioHarmony Engine v2.0
Key Evidence Sources
- Dinda et al. 2015 - Oroxylum indicum (L.) Kurz, an important Asian traditional medicine: from traditional uses to scientific data for its commercial exploitation, Journal of Ethnopharmacology. A comprehensive review of Oroxylum indicum that gathers its traditional Asian uses alongside the plant's phytochemistry, pharmacology, and toxicology data.
- Lopresti et al. 2021 - Effects of an Oroxylum indicum Extract (Sabroxy) on Cognitive Function in Adults With Self-reported Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Study, Frontiers in Aging Neuroscience. A randomized placebo-controlled trial testing 500 mg per day of the Sabroxy extract for 28 days in adults with self-reported mild cognitive impairment, reporting cognitive improvements and raised BDNF.
- PubChem compound database. The NIH chemical database used to confirm the structure and identity of oroxylin A, the active compound in the extract.
- MedlinePlus herbs and supplements. The NIH consumer reference for herbs and supplements, used as background on botanical safety and interaction context.
- NIH Office of Dietary Supplements. The federal office that publishes evidence summaries and safety guidance on dietary supplements.
- FDA Dietary Supplements overview. The FDA regulatory page explaining how dietary supplements like this extract are regulated and labeled in the United States.
- World Anti-Doping Agency prohibited list. The official prohibited substances list athletes use to check competition rules before adding any new supplement.
- PubMed biomedical literature database. The primary NIH literature database used to locate and verify the human and review studies cited in this report.
What does the evidence say about Sabroxy (Oroxylum indicum Extract)?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Low
Citations: Lopresti 2021, Dinda 2015
Pre-RCT-Era Pharmacology and Use
Citations: Dinda 2015
Traditional Medicine Systems
Confidence: Limited
Citations: Dinda 2015
Holistic Evidence for Sabroxy (Oroxylum indicum Extract)
Sabroxy has historical botanical context, but the modern score depends on the small branded-extract human trial and independent replication.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Blood Pressure Baseline (pre-protocol)
- Sleep Duration During | Expected Watch
Pulse Dimensions to Watch
- Drive During | Expected Up | Primary
- Energy During | Expected Up | Secondary
- Sleep During | Expected Watch | Secondary
Subjective Signals (Daily Voice Card)
- Working Memory Scale 1-5 | During | Expected Up
- Overstimulation Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Serotonergic, dopaminergic, or MAOI medication conflicts
- Insomnia, agitation, or elevated blood pressure
Other interventions for Cognition & Focus
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–2.9, Caution 3.0–4.4, Neutral 4.5–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–8.7, Top-tier 8.8–10.0.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.295 − 1.055 = 1.240
Formula v2.0 maps EV = 0 to score 5.0. Above neutral, EV = +4.00 reaches 10.0; below neutral, EV = −5.36 reaches 0.0. Both sides use the full 5-point half-scale.
Score = 5 + (1.240 / 4.00) × 5 = 6.6 / 10
